|
[1]
|
李琴, 檀鑫, 姜文溪, 袁梦, 倪慧, 王媛, 杜杰. 急性心肌梗死患者经皮冠状动脉介入治疗后远期主要不良心血管事件预测模型的构建[J]. 中国全科医学, 2022, 25(24): 2965-2974.
|
|
[2]
|
Stundl, A., Lünstedt, N.S., Courtz, F., et al. (2017) Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 120, 986-993. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Pascual-Figal, D.A., Januzzi, J.L. (2015) The Biology of ST2: The International ST2 Consensus Panel. American Journal of Cardiology, 115, 3B-7B. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Tominaga, S. (1989) A Putative Protein of a Growth Specific cDNA from BALB/c-3T3 Cells Is Highly Similar to the Extracellular Portion of Mouse Interleukin 1 Receptor. FEBS Letters, 258, 301-304. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Yanagisawa, K., Takagi, T., Tsukamoto, T., et al. (1993) Presence of a Novel Primary Response Gene ST2L, Encoding a Product Highly Similar to the Interleukin 1 Receptor Type 1. FEBS Letters, 318, 83-87. [Google Scholar] [CrossRef]
|
|
[6]
|
Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., et al. (2002) Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation, 106, 2961-2966. [Google Scholar] [CrossRef]
|
|
[7]
|
Schmitz, J., Owyang, A., Oldham, E., et al. (2005) IL-33, an Interleukin-1-Like Cytokine That Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Broch, K. andreassen, A.K., Ueland, T., et al. (2015) Soluble ST2 Reflects Hemodynamic Stress in Non-Ischemic Heart Failure. International Journal of Cardiology, 179, 378-384. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Yucel, O., Gul, I., Zararsiz, A., et al. (2018) Association of Solu-ble ST2 with Functional Capacity in Outpatients with Heart Failure. Herz, 43, 455-460. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Cayrol, C., Girard, J.P. (2018) Interleukin-33 (IL-33): A Nuclear Cytokine from the IL-1 Family. Immunological Reviews, 281, 154-168. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Liu, X., Hammel, M., He, Y., et al. (2013) Structural Insights into the Interaction of IL-33 with Its Receptors. Proceedings of the National Academy of Sciences of the United States of America, 110, 14918-14923. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Allencherril, J., Jneid, H., Atar, D., et al. (2019) Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovascular Drugs and Therapy, 33, 589-597. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Durante, A., Camici, P.G. (2015) Novel Insights into an “Old” Phenomenon: The No Reflow. International Journal of Cardiology, 187, 273-280. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Somuncu, M.U., Akgun, T., Cakır, M.O., et al. (2019) The Ele-vated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percu-taneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 26, 970-978. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Sondergaard, F.T., Beske, R.P., Frydland, M., et al. (2022) Soluble ST2 in Plasma Is Associated with Post-Procedural No-or-Slow-Reflow after PCI in ST-Elevation Myocardial Infarction. Euro-pean Heart Journal. Acute Cardiovascular Care, zuac146. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Zhang, Q., Hu, M. and Ma, S. (2021) Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coro-nary Intervention. Journal of Atherosclerosis and Thrombosis, 28, 1289-1297. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Yousef, Z.R., Redwood, S.R. and Marber, M.S. (2000) Post-Infarction Left Ventricular Remodelling: Where Are the Theories and Trials Leading Us? Heart, 83, 76-80. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Yao, H.C., Li, X.Y., Han, Q.F., et al. (2015) Elevated Serum Soluble ST2 Levels May Predict the Fatal Outcomes in Patients with Chronic Heart Failure. International Journal of Cardiology, 186, 303-304. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Shah, R.V. and Januzzi, J.L. (2014) Soluble ST2 and Galectin-3 in Heart Failure. Clinics in Laboratory Medicine, 34, 87-97, vi-vii. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Miller, A.M. and Liew, F.Y. (2011) The IL-33/ST2 Pathway—A New Therapeutic Target in Cardiovascular Disease. Pharmacology & Therapeutics, 131, 179-186. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Zhang, T., Xu, C., Zhao, R. and Cao, Z. (2021) Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medi-cine, 8, Article ID: 697837. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Sutton, M.G. and Sharpe, N. (2000) Left Ventricular Remodeling after Myocardial Infarction: Pathophysiology and Therapy. Circulation, 101, 2981-2988. [Google Scholar] [CrossRef]
|
|
[23]
|
Tseng, C.C.S., Huibers, M.M.H., van Kuik, J., et al. (2018) The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-Fibrotic Remodeling of the Myocardium. Journal of Cardiovascular Translational Research, 11, 15-21. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Pecherina, T., Kutikhin, A., Kashtalap, V., et al. (2020) Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myo-cardial Infarction in Patients with Preserved Ejection Fraction. Diagnostics (Basel), 10, 301. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Zhao, L., Li, S., Zhang, C., et al. (2021) Cardiovascular Magnet-ic Resonance-Determined Left Ventricular Myocardium Impairment Is Associated with C-Reactive Protein and ST2 in Patients with Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Magnetic Resonance, 23, 30. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Huttin, O., Kobayashi, M., Ferreira, J.P., et al. (2021) Circulat-ing Multimarker Approach to Identify Patients with Preclinical Left Ventricular Remodelling and/or Diastolic Dysfunc-tion. ESC Heart Failure, 8, 1700-1705. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Ip, C., Luk, K.S., Yuen, V.L.C., et al. (2021) International Health Infor-matics Study (IHIS) Network. Soluble Suppression of Tumorigenicity 2 (sST2) for Predicting Disease Severity or Mor-tality Outcomes in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. IJC Heart & Vasculature, 37, Ar-ticle ID: 100887. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
徐芳, 徐俊杰, 吴春苑, 匡龙, 宋佳贤, 李海刚, 钱雪松, 王莉. 左室心肌做功对急性心肌梗死患者急诊PCI术后MACE发生的预测价值[J]. 临床心血管病杂志, 2022, 38(12): 960-966. [Google Scholar] [CrossRef]
|
|
[29]
|
蔡娟, 周陵. 急性心肌梗死4天时血清可溶性生长刺激表达基因2蛋白水平与6个月内心原性死亡关系的研究[J]. 中国循环杂志, 2019, 34(5): 467-471.
|
|
[30]
|
殷昌斌, 张健平, 李家伟, 任慧. 急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后血清C1q/肿瘤坏死因子相关蛋白3、可溶性生长刺激表达基因2蛋白和Elabela水平与预后的相关性[J]. 中国医师进修杂志, 2022, 45(7): 618-623.
|
|
[31]
|
Zagidullin, N., Motloch, L.J., Gareeva, D., Hamitova, A., et al. (2020) Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine, 9, 550. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Somuncu, M.U., Avci, A., Kalayci, B., et al. (2021) Predicting Long-Term Cardiovascular Outcomes in Myocardial Infarction Survivors Using Multiple Biomarkers. Biomarkers in Medicine, 15, 899-910. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
刘巍, 何伶俐. 血清可溶性生长刺激表达基因2蛋白、白介素-17在经皮冠状动脉介入治疗急性非ST段抬高型心肌梗死患者预后评估中的价值研究[J]. 实用医院临床杂志, 2020, 17(4): 218-221.
|